Sandoz raises 2026 core EBITDA margin guidance to 23.0%-23.5%

• Sandoz narrowed 2026 net sales growth guidance to 5-6% at constant currencies, from mid-to-high single digits.
• Core EBITDA margin guidance rose to 23-23.5%, versus roughly 100 basis points of expansion previously expected from 2025’s 21.7%.
• Temporary biosimilar supply constraints in Europe and International, alongside tougher German market conditions, prompted the sales guidance revision.
• A more favorable sales mix and stronger operational performance supported the margin upgrade; core earnings per share expectations also improved.
• Third-quarter sales grew 5% at constant currencies, with biosimilars up 17%; outlooks through 2028 and 2030 remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2423270_en) on October 28, 2026, and is solely responsible for the information contained therein.